""Question for anybody; does the market recognize that the latest funding deal is guaranteed?, and if so, that it will push the company to a rerate or not?, overhang of SB should be just about gone. On that note why is getting a copy of the Top Twenty like trying to get the Coke Cola recipe, lol.""
Nearly 50% up since the funding deal says to me that it was a positive, further appreciation would depend on coming up news:
1) Result of the TAVR in animal studies
2) Result of AVR tissue against the leading TAVR makers tissue
3) FDA approval for in human TAVR Trial
4) Company indicated before that they would enter the CABG market which is huge on it's own, I am sure everyone knows someone who had a bypass.
as for the top 20, since SB started selling I asked and got about 10 top20's as I was tracking SB sell down, rang the company office, then in turn they gave me a number to call, since then I call that number and within the same day I get the top20. I got told not to share it publicly and I never did.
I still have a screenshot of a post of yours that you quickly asked HC to delete afterwards, you posted a top20, I wouldn't blame the company for not giving you the top20 after that or making it hard for you. Although the company used to publish the top20 before, they are under no obligation what so ever to publish them if they don't want to, but it is within the right of every holder to ask for it, even none holders can ask for it for a fee.
although I am deeply in the red like you, I have switched from half empty to half full cup after the funding deal, hopefully finally blue sky from here on.
all the best
Charles
- Forums
- ASX - By Stock
- AVR
- Star Bright
Star Bright, page-15
-
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.90 |
Change
-0.100(1.00%) |
Mkt cap ! $208.2M |
Open | High | Low | Value | Volume |
$10.00 | $10.00 | $9.65 | $46.79K | 4.766K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 361 | $9.80 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.90 | 84 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 53 | 9.790 |
3 | 1112 | 9.780 |
1 | 180 | 9.750 |
1 | 150 | 9.730 |
1 | 150 | 9.720 |
Price($) | Vol. | No. |
---|---|---|
9.900 | 133 | 1 |
9.910 | 567 | 2 |
9.990 | 265 | 2 |
10.000 | 794 | 2 |
10.500 | 10005 | 2 |
Last trade - 13.38pm 12/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online